Regeneron director Sing proposes $958K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Regeneron Pharmaceuticals, Inc. (REGN) is the issuer named in director George L. Sing’s notice of a proposed sale of 1,000 common shares, with an approximate sale date of November 17, 2026 and an aggregate market value of $957,687.10. The notice reports 101,630,713 common shares outstanding. It also lists sales of 1,000 shares for gross proceeds of $960,264.40 on November 16, 2026, and 21,129 shares for gross proceeds of $20,376,359.76 on November 2, 2026.
Key Figures
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.